Patanol (Olopatadine) Drug Information: Warnings and Precautions

Pill Identifier Search

May 27, 2012

Patanol

Allergy Drugs: Prescription and OTC »

Allergy medications overview

The arsenal of allergy drugs includes dozens of medications that relieve allergy symptoms when confronted with a trigger known as an allergen. That trigger could be something from a plant, such as pollen, or something from an animal (pet dander, dust mites, cockroaches). Other allergy triggers include certain fragrances or chemical substances.

What causes a person's allergic reaction is highly individual. But the reactions are often universal: swelling and inflammation, especially around the eyes, nose, and throat, usually accompanied by itching.

Some allergy medications work against the effects of histamines, which are released during an allergic reaction. Other medications reduce swelling, affect the immune system, or affect release of other substances associated with allergic reactions.

Many allergy drugs are available without a prescription.

For what conditions are allergy medicatio...

Read the Allergy Drugs: Prescription and OTC article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Patanol User Reviews >>

Patanol

Eye Diseases and Conditions Slideshow Pictures

Pink Eye Slideshow Pictures

Cataracts Slideshow Pictures

font size

WARNINGS

PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is for topical use only and not for injection or oral use.

PRECAUTIONS

Carcinogenesis, Mutagenesis, Impairment of Fertility: Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 µL drop size, these doses were 78,125 and 31,250 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of 62,500 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of 7,800 times the maximum recommended ocular human use level.

Pregnancy: Pregnancy Category C. Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however, no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

Nursing Mothers: Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is administered to a nursing mother.

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Last reviewed on RxList: 3/17/2008
This monograph has been modified to include the generic and brand name in many instances.